Risankizumab Antibody

SKU: orb1980665

Description

Risankizumab is a high-affinity humanized monoclonal antibody targeting the IL-23 p19 subunit, potently inhibiting IL-23-driven IL-17 production with an IC50 of 2 pM in vitro. It is a key research tool for studying Th17-mediated pathologies like psoriasis and psoriatic arthritis, with applications in both cellular assays and preclinical in vivo models.

Research Area

Immunology & Inflammation

Key Properties

• CAS Number: 1612838-76-2
• MW: 145.85 kDa
• Purity: 98.3% (SEC-HPLC)
• Target: Interleukin,IL Receptor

Bioactivity

• Target IC50:
  IL-23:10pM (kd,human)|IL-23:10pM (kd,cynomolgus)|IL-17:17 pM (cynomolgus)|IL-17:2 pM (human)
• In Vivo:
  In mice, Risankizumab (BI 655066) inhibits IL23-induced ear swelling and cytokine production following a single intraperitoneal (i.p.) dosage of 1 mg/kg.
• In Vitro:
  With Kds <10 pM, Risankizumab (BI 655066) exhibits high affinity for human and cynomolgus IL23. Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC50s of 2 pM and 17 pM, respectively.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ILReceptor, IL Receptor, IL-23, BI-655066, ABBV 066, SKYRIZI, Risankizumab rzaa

Quick Database Links

Gene Symbol

Interleukin,IL Receptor